Skip to main content
. 2019 Dec;47(12):1403–1414. doi: 10.1124/dmd.119.088716

Fig. 6.

Fig. 6.

The effect of a pharmacological inhibitor of efflux transport, elacridar, on the plasma and brain concentration of SAR405838. (A) Concentrations in plasma and brain at 2- and 6-hour postdose with coadministration of either vehicle control or inhibitor, either LY335979 or elacridar. (B) Brain-to-plasma ratio at 2- and 6-hour postdose. Data presented as mean ± S.D. where N = 3–5 for each group. **P < 0.01; ***P < 0.005.